

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

Date of Report (Date of earliest event reported): **March 8, 2023**

HEARTBEAM, INC.

(Exact name of Registrant as specified in its charter)

Delaware

(State or other jurisdiction
of incorporation)

001-41060

(Commission File Number)

47-4881450

(IRS Employer
Identification No.)

2118 Walsh Avenue, Suite 210

Santa Clara, CA 95050

(Address of principal executive offices, including zip code)

(408) 899-4443

(Registrant's telephone number, including area code)

Check the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	BEAT	NASDAQ
Warrant	BEATW	NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

ITEM 7.01. REGULATION FD DISCLOSURE

HeartBeam, Inc. (the "Company") expects to use the presentation attached to this Current Report on Form 8-K as Exhibit 99.1 (the "Investor Deck Presentation") and incorporated herein by reference, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others.

The information contained in the Investor Deck Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission ("SEC") filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, except as required by law although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

Notwithstanding the foregoing, the information presented in Item 7.01 of this Current Report on Form 8-K is to be considered incorporated by reference into the Registration Statement on Form S-1, No. 333-269717, of the Company.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Exhibit Number	Description
99.1	Investor Deck Presentation March 2023
104	Cover Page Interactive Data File, formatted in InLine XBRL and included as Exhibit 101

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

HeartBeam, Inc.


Date: March 10, 2023

By: /s/ Richard Brounstein
Name: Richard Brounstein
Title: Chief Financial Officer



Breakthrough Cardiac Health Monitoring

Always by your side



1

Disclaimers

This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company's future results of operations and financial position, planned products and services, business strategy and plans and objectives of management for future operations, are forward-looking statements.

These statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "aims," "predicts," "potential," "seeks," "attempts," "poised" or "continues" or the negative of these terms or other similar words. These statements are only predictions.

The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Also, these forward-looking statements represent the Company's estimates and assumptions only as of the date of this presentation. The Company assumes no obligation to update any forward-looking statements after the date of this presentation.

This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other industry data. This data involves several assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The Company has not independently verified the statistical and other industry data generated by independent parties and contained in this presentation and, accordingly, it cannot guarantee their accuracy or completeness.

In addition, projections, assumptions and estimates of its future performance and the future performance of the industries in which it operates are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause results to differ materially from those expressed in the estimates made by independent parties and by the Company. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see disclosures contained in HeartBeam's public filings with the SEC, including the "Risk Factors" in HeartBeam's Annual Report on Form 10-K, and which may be viewed at www.sec.gov.

The HeartBeam telemedicine technology platform has not yet been evaluated by the FDA and is not approved for clinical use in the USA or other global geographies.

2

A Practical & Portable Solution To Replicate 12-Lead ECG Is Needed

Current portable heart monitoring solutions only offer basic monitoring



Practical, portable devices currently in the market **can not** replicate the gold standard 12-lead ECG



Single-lead options are limited only to sense heart arrhythmias



Only a 12-lead ECG can suggest heart attack



High number of false positives in single-lead devices leads to users ignoring suggestions and overwhelms clinicians



Limited applications and predictive value

Heart Disease Kills 17.9 Million People Per Year


Better diagnosis can improve the management of heart conditions



More in-depth and longitudinal data might lead to earlier diagnosis of heart diseases



Multiple heart conditions can be diagnosed with richer data set



Fast and accurate heart attack suggestion can improve patient outcomes

Outcomes Can Be Improved With Early Heart Attack Diagnosis

First ambulatory device to detect heart attack

Ignore Symptoms


Lost Lives

- Patients delay an average of 3 hours before seeking care
- Delays lead to increased mortality
- Greater incidence of heart failure among these patients

Mortality rate increases by

40%

for an average wait 3-4 hours after symptoms begin



Am I having a heart attack?

Go To Emergency Department

Wasted Healthcare Dollars

- Chest pain is second most common reason for an ED visit

82% of chest pain ED visits are unnecessary


\$10B

Cost to the healthcare system each year

Leader In Ambulatory Vectorcardiography

Vectorcardiography Simplified


- Vectorcardiography has clear advantages over ECG*, but additional electrodes and difficulty of interpretation has hampered its use
- VECG - Unique design allows for measuring 3D heart signals in a portable form factor
- 3D information can be synthesized into 12-lead ECG
- Data collection advantage can be leveraged into algorithms and AI predictive models



Click on image to watch video

*Source: Pérez Riera, et al (2007). Significance of vectorcardiogram in the cardiological diagnosis of the 21st century. *Clinical Cardiology*, 30(7), 319–323. <https://doi.org/10.1002/clc.14>

Unlocks Conditions Beyond Arrhythmias



7

Competing Devices Offer Basic Monitoring

	HeartBeam	Apple WATCH	AliveCor®	Rhythm
HEART ATTACK DETECTION	✓	✗	✗	✗
12L ECG CAPABLE	✓	✗	✗	✗
INTEGRATES HISTORY & SYMPTOMS	✓	✗	✗	✗
USES BASELINE	✓	✗	✗	✗
LONG TERM USE POTENTIAL	✓	✓	✓	✗
AFIB DETECTION	✓	✓	✓	✓
AFLUTTER DETECTION	✓	✗	✗	✓


HeartBeam AIMI™ and HeartBeam AIMIGo™ have not yet been evaluated by the FDA and are not approved for clinical use in the USA or other global geographies.

8




Telehealth Application

Current options are fundamentally limited, especially in ability to detect heart attacks.



12-Lead ECG System Always With You

Practical ECG System



Powerful Heart Monitoring In Your Pocket

Portable Vector Electrocardiogram (VECG)



12-Lead ECG

- Technology can replicate a 12-lead ECG in a true portable form factor
- Allows for rich data acquisition with better diagnosis and predictive value, thanks to the 58 parameters that can be measured



Validation Trials

- Similar accuracy to cardiologist panel in ACS detection (BSCORE trial)
- Better accuracy than panel of cardiologists in early Myocardial Infarction (MI) detection (HIDES trial)



Familiar Output

- Familiar 12-lead ECG readout eliminates cardiologists' learning curve
- Diagnosis suggestive algorithm



Regulatory Strategy

- Designed a staggered regulatory approach for a well-traveled 510(k) regulatory path


HeartBeam AIMI™ and HeartBeam AIMiGo™ have not yet been evaluated by the FDA and are not approved for clinical use in the USA or other global geographies.

Excellent Performance In Multiple Settings

Validation

MI Detection

Unique 3D ECG interpretation method has greater accuracy than cardiologists in detecting MIs




HIDES STUDY
N = 186 recordings; 66 subjects

* HIDES study was conducted to assess early Myocardial Infarction detection. MI was induced via a balloon catheter occlusion. Utilized baseline measurements.

Chest Pain Triage

Proprietary algorithm performance equal to standard of care in chest pain triage



BSCORE STUDY
N = 110 subjects (# of subjects to successfully record a reverse baseline measurement)

* BSCORE study was conducted in an Emergency Room setting and utilized baseline measurements to aid the high sensitivity achieved.

Asymptomatic


No heart attack (MI) false positives in asymptomatic patients, big data potential




ISPECT STUDY
N = 1,485 recordings; 30 patients

* ISPEC study utilized non-symptomatic patients.


Regulatory Strategy To Establish VECG As The Gold Standard



Platform Enables Multiple Paths To Market




Value Creation Timeline




*This timeline is for illustrative purposes only and is meant to portray a sequence of events, not their estimated timing.

Functionality & Scale Drive Value



AIMiGo Potential Market Segments



Leadership Opportunity In Portable VECG Space

Intellectual Property & Product Pipeline



Card

- Multiple granted patents, including foundational resistive network enabling Z-lead
- Potential additional patents around improving accuracy and business model
- Additional prototypes to lower cost



Patch

- Foundational patent granted: VECG to 12-lead upon pressing electrodes with fingers
- Capital being allocated to develop prototype



Smart Watch

- Foundational patent granted: VECG to 12-lead upon placing band electrodes on chest

Licensing Opportunities on Multiple Fronts



ECG Devices



ECG Patch



Smartwatches



Key Medical Contributors

World Class Advisors



MIKE GIBSON, MD
PETER ZIMETBAUM, MD
ALEXEI SHVILKIN, MD



NIRAJ VARMA, MD
STEVE ELLIS, MD



PETER FITZGERALD, MD, PhD
PHILIP SAGER, MD
RAJ DASH, MD



JOHN JEFFERIES, MD



TOM DEERING, MD



CHARLIE BROWN, MD
JEFFREY J. OYLER, MD



BARRY MANGEL, MD
BRETT CANNON, MD

Highly Experienced Management

Significant experience in software & medical device product development



Branislav Vajdic, PhD
CEO & Founder



Rob Eno
President



Rick Brounstein
Chief Financial Officer



Peter Fitzgerald, MD, PhD
Chief Medical Officer



Ken Persen
Chief Technical Officer



Rich Ferrari
Executive Chairman



Marga Ortigas-Wedekind
Board Member



Wim Elfrink
Board Member



George de Urioste
Board Member



21

Cap Structure

Common Stock

Total Outstanding Shares	8,004,620
--------------------------	-----------

Stock Options

Stock Options	Number of Stock Options	Weighted Avg. Exercise Price
Outstanding Sept. 30, 22	2,101,921	\$1.69
Vested Sept. 30, 22	556,005	\$1.33

Warrants

Warrants	Number of Warrants	Weighted Avg. Exercise Price
Outstanding Sept. 30, 22	3,908,276	\$5.43
Exercisable Sept. 30, 22	3,501,004	\$6.06





Notes:

Weighted average remaining contractual life in years for outstanding options is 8.9 years.
 Weighted average remaining contractual life in years for exercisable options is 7.3 years.
 Weighted average remaining contractual life in years for outstanding warrants is 3.7 years.
 Weighted average remaining contractual life in years for exercisable warrants is 4.1 years.

22



The Offering

 Offering Amount \$15 Million	 Security Straight Common Stock
 Price Per Share To Be Determined	 Offer Type Registered Public Offering

23

Use Of Proceeds

Enables 12-month runway to reach value-inflection milestones

In thousands

Clinical & Regulatory	\$2,000
Research & Development	\$7,000
Sales & Marketing	\$1,000
General & Administrative	\$5,000
Total	\$15,000

24

Novel Way To Capture Rich Electrical Signal Data From The Heart

Investment Highlights



12-Lead ECG

- Only device you can carry in your pocket that can replicate the gold standard 12-lead ECG
- Allows for rich data acquisition with better diagnosis and predictive value



Intellectual Property

- Foundational patents in the portable VECG space including multiple form factors
- Opportunity to define the VECG space



Potential Headroom

- Richer data set coupled with AI + ML could help diagnose many heart related conditions
- Comprehensive heart picture with VECG could become the gold standard in heart diagnosis



Value Inflection

- Companies with fewer capabilities trading above multi-billion dollar valuations
- FDA clearances expected in the next 12 months


HeartBeam AIMI™ and HeartBeam AIMIGo™ have not yet been evaluated by the FDA and are not approved for clinical use in the USA or other global geographies.

25



Breakthrough Cardiac Health Monitoring

Always by your side



26